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Abstract
The ecotropic viral integration site 1 (Evi1) oncogenic transcription factor is one of a number of alternative transcripts
encoded by the Mds1 and Evi1 complex locus (Mecom). Overexpression of Evi1 has been observed in a number of myeloid
disorders and is associated with poor patient survival. It is also amplified and/or overexpressed in many epithelial cancers
including nasopharyngeal carcinoma, ovarian carcinoma, ependymomas, and lung and colorectal cancers. Two murine
knockout models have also demonstrated Evi1’s critical role in the maintenance of hematopoietic stem cell renewal with its
absence resulting in the death of mutant embryos due to hematopoietic failure. Here we characterize a novel mouse model
(designated Evi1fl3) in which Evi1 exon 3, which carries the ATG start, is flanked by loxP sites. Unexpectedly, we found that
germline deletion of exon3 produces a hypomorphic allele due to the use of an alternative ATG start site located in exon 4,
resulting in a minor Evi1 N-terminal truncation and a block in expression of the Mds1-Evi1 fusion transcript. Evi1dex3/dex3
mutant embryos showed only a mild non-lethal hematopoietic phenotype and bone marrow failure was only observed in
adult Vav-iCre/+, Evi1fl3/fl3 mice in which exon 3 was specifically deleted in the hematopoietic system. Evi1dex3/dex3 knockout
pups are born in normal numbers but die during the perinatal period from congenital heart defects. Database searches
identified 143 genes with similar mutant heart phenotypes as those observed in Evi1dex3/dex3 mutant pups. Interestingly, 42
of these congenital heart defect genes contain known Evi1-binding sites, and expression of 18 of these genes are also
effected by Evi1 siRNA knockdown. These results show a potential functional involvement of Evi1 target genes in heart
development and indicate that Evi1 is part of a transcriptional program that regulates cardiac development in addition to
the development of blood.
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Introduction
The complexity of an organism is defined not only by the
number of its genes, but also how expression of these genes is
controlled. This also includes several post-transcriptional events
that control protein production, including alternative splicing,
translational repression, microRNA-induced mRNA degradation,
and the regulated generation of distinct gene products through the
alternative use of translational initiation sites. These various
mechanisms provide a tremendous diversity of protein sequence,
structure and function [1,2]. Much improvement has been made
in defining the molecular basis of these regulations. However, it
remains a major challenge to integrate this knowledge into a
complete understanding of the resulting physiological functions, in
normal and pathological conditions.
The MDS1 and EVI1 complex locus (MECOM) contains
several transcription start sites and alternative splice options. It
produces multiple transcripts coding for nuclear transcription
factors. One of its major gene products is ecotropic viral
integration site 1 (EVI1), an oncogenic zinc finger transcription
factor (TF) whose overexpression in myeloid disorders such as
acute and chronic myeloid leukemia (AML and CML), and
myelodysplastic syndrome (MDS) has been extensively studied and
correlated with poor patient survival [3–5]. Amplification and/or
overexpression of EVI1 have also been observed in multiple
epithelial cancers, including nasopharyngeal carcinoma, ovarian
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carcinoma, ependymomas, and lung and colorectal cancers [6–
11]. In addition, EVI1 controls several aspects of embryonic
development including hematopoiesis where it has been shown to
be important for hematopoietic stem cell (HSC) renewal [12] and
angiogenesis [13]. The most oncogenic human MECOM isoform,
EVI1, encodes a 1051 amino acid protein containing two zinc
finger domains, a central transcriptional repression domain and an
acidic C-terminal region [5,14,15]. The seven zinc finger domains
located in the N-terminus are known to bind to a GATA-like
consensus motif [13,16–19], while the three zinc finger domains in
the C-terminus bind to an ETS-like motif [16,20]. Additional
alternative splicing of MECOM in human and mouse produces,
amongst others, two major isoforms, EVI1d324 and MDS1-EVI1
[5,14,15,21]. MDS1-EVI1 is a larger MECOM variant. Although
MDS1 was originally described as a distinct gene, it is now
recognized to be an alternative transcription start site and part of
the MECOM locus. MDS1-EVI1 contains a 188 amino acid
extension at its N-terminus, adding the so-called PR domain,
which is a derivative of the SET domain [5,14,15,22]. Several lines
of evidence suggest that the form of EVI1 lacking the PR domain
and MDS1-EVI1 display opposite functions. The shorter isoform
(EVI1) acts as an aggressive oncogene while expression of the
longer isoform (MDS1-EVI1) is linked to good prognosis in cancer
[23–25]. MDS1-EVI1 was also recently described as a regulator of
long term HSC repopulating activity [21]. Another important
MECOM isoform, called EVI1d324, resembles EVI1 but lacks
zinc fingers motifs 6 and 7, which prevents its binding to GATA-
like sites. Additional alternative splicing lead to the deletion of 9aa
in the repressor domain of EVI1, MDS1-EVI1, or EVI1d324
[14,26–28], thus producing additional isoforms.
The exact physiological roles of these various MECOM products
remain to be characterized. Two mouse knockout models have
been previously reported that target MECOM. The first one was
produced by deletion of Evi1 exon 7 [13,29] while the second
represents a conditional deletion of exon 4 [12]. For both alleles,
homozygous Evi1-/- mice resulted in the deletion of both Evi1 and
Figure 1. Deletion of Evi1 exon3 generates a hypomorphic allele. (A) Sequenced products obtained after 59RACE from wild type or Evi1dex3/
dex3 mutant embryos. (B) Table showing the fraction of embryos of each genotype detected at different stages of embryonic development. The
Mendelian ratios were not affected by the Evi1 exon3 deletion. (C) Pictures of 28 hr-old littermates highlight the poor health of dying Evi1dex3/dex3
pups. (D) Kaplan-Meyer curves for wild type, Evi1dex3/+ and Evi1dex3/dex3 progeny indicate lethality of all Evi1dex3/dex3 pups by three days after birth
(n = 5 to 16 per genotype). Log rank test, Chi square p value ,0.0001. (E) RT-qPCR from cDNA of E14.5 embryos. The primers used amplified the
regions between Evi1 exons 2 and 3, 3 and 4 or 13 and 14. Mean of three different samples per condition. The standard deviation is shown. (F)
Expression of Evi1 and c-tubulin protein products in E14.5 wild type or E17.5 Evi1dex3/+ and Evi1dex3/dex3 mutant embryos (100 mg protein/lane). (G)
Nucleotide sequence of Evi1 cDNA in the exon 3 and 4 genomic region. Two ATG sites are present in exon 3 and one in exon 4. All ATGs are
conserved in higher vertebrates.
doi:10.1371/journal.pone.0089397.g001
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Mds1-Evi1 transcripts. Both phenotypes showed embryonic
lethality and impairment of hematopoiesis due to the loss of
HSC renewal ability.
In this study, we analyzed a new conditional mutant allele of
Mecom that was produced by flanking Evi1 exon 3, also Mds1-
Evi1 exon 4, with loxP sites. The removal of Evi1 exon 3 is
predicted to generate a frame shift mutation that would block the
translation of Mds1-Evi1 protein. As Evi1 and Evi1d324 both have
translational initiation site located in exon3, it was also predicted
that their protein expression would be blocked. However, Evi1
and Evi1d324 proteins are produced in Evi1dex3/dex3 tissues, likely
due to an alternative translation start site located in exon 4. Thus,
only the Mds1-Evi1 isoform is fully disrupted in Evi1dex3/dex3 mice.
Evi1dex3/dex3 animals do not die in utero and display a different
phenotype compared to exon 4 and 7 knockout mice. The analysis
of this new hypomorphic exon 3 Evi1 allele has uncovered novel
physiological functions for MECOM in the formation of the
circulatory system and provided a better understanding of the
function of the various MECOM transcripts.
Experimental Procedures
Animals
The Institute of Molecular and Cell Biology Animal Care and
Use Committee approved all animal protocols used in this study.
The Evi1 exon 3 floxed allele, Evi1fl3 [21], was maintained in a
pure C57BL/6 background. After crossing to a b-actin-Cre deleter
strain to generate the Evi1dex3 null allele, Evi1dex3 bearing mice
were a mixture of strains 129/Sv and C57BL/6. They were made
congenic on a C57BL/6 background over the course of the study,
with no observed change in the experimental results. Mice were
genotyped by PCR using primers F1 (59- GGAGTGT-
TAAGCTTGAATTCC-39), F2 (59-GAAGAGCTCTTGCTG-
TTCATG-39), and R7 (59- CAGCTTAGACCTCAGCTAAC-
Figure 2. Disruption of hematopoiesis in Evi1dex3/dex3 newborn mice. (A,B) Flow cytometric profiles of wild type, Evi1dex3/+ and Evi1dex3/dex3
littermate fetal livers at E14.5. (A) HSC and progenitor cell subpopulations were detected by a combination of markers (KSL: c-Kit+, S: Sca-1+, L:
lineage2, or KL-CD34+). We found a significant reduction of cells in the Evi1-deleted samples; p values are from an unpaired t-test between +/+ and
Evi1dex3/dex3 fetal livers. (B) Bar graph shows the number of granulocytes (Gr1), B-lymphocytes (B220) and erythroid cells (Tert119) in fetal livers of
various different genotypes. (C) Colony forming counts from cells of 3 fetal livers of each genotype at E14.5 We observed a significant reduction in
colony formation between +/+ and Evi1dex3/dex3 fetal livers, p = 0.0057 (unpaired t-test). No BFU-E or CFU-Mix colonies were identified. (D) Hemogram
results for 4 hr- to 24 hr-old wild type (N= 17), Evi1dex3/+, (N = 30) and Evi1dex3/dex3 (N= 16) littermate pups. Mean 6 SEM is indicated. *p,0.05,
**p,0.01, ***p,0.001, unpaired t-test. Leukocyte counts in peripheral blood and white blood cell differentials reveal a mild leucopenia in Evi1dex3/
dex3 newborn mice. Platelet (PLT) counts and mean platelet volume (MPV) results show a mild hypoproliferative thrombocytopenia in Evi1dex3/dex3
pups. Normal erythrocyte counts, hemoglobin quantification and hematocrit assessment in the peripheral blood of Evi1dex3/dex3 animals. Mean
corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC) and red cell distribution
widths (RDW) are shown. (E) Hematoxylin and eosin staining of 5 mm sections of 24 hr- to 48 hr-old Evi1dex3/dex3 pups. Mild hemorrhages were seen in
31% of the mice (4 out of 13 pups).
doi:10.1371/journal.pone.0089397.g002
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39). F2 and R7 were used to discriminate between the Evi1fl3
(375 bp) and wild type (269 bp) alleles. F1 and R7 were used to
detect the Evi1dex3 allele (125 bp) (Fig. S1A,B in File S1). Vav-iCre
was genotyped using Cre-F (59-GCCTGCATTACCGGTC-
GATGCAACGA-39) and Cre-R (59-GTGGCAGATGGCGCG-
GCAACACCATT-39) primers (700 bp amplicon). Blood was
obtained by retro-orbital bleeding for adult mice, and by
decapitation for embryos. Blood counts were performed with a
Hemavet 950 device.
Quantitative real time RT-PCR (qRT-PCR)
RNA was isolated from mouse tissues using Trizol and an
RNeasy Mini Kit (Qiagen), and 0.5–2 mg were used for cDNA
synthesis (SuperScript III First-Strand Synthesis; Invitrogen) with
oligodT. qPCR was performed with the ABI-Prism 7500 (Applied
Biosystems), SYBR green Master Mix, and primers designed with
Primer Express Software v2.0 (Applied Biosystems). A primer list is
provided in File S1. We used the 22ddCt method [30] to calculate
the fold change of expression. Relative expression was normalized
to Tubg1 mRNA levels.
Protein extraction and immunoblotting
Snap frozen tissues were processed for protein extraction as
previously described [31]. Immunoblotting was performed using a
protocol previously described [16]. Evi1 antibody was produced in
rabbits [19] and c-tubulin antibody was from Sigma.
HSC characterization
Hematopoietic cells were extracted from the fetal liver or bone
marrow. Flow cytometric analyses and cell sorting were performed
using a LSR II, a fluorescence-activated cell sorter (FACS)
Vantage, or a FACSAria as previously described [32]. Antibodies
were purchased from BD Biosciences: PE-conjugated anti-Gr1
(RB6-8C5), Mac-1 (M1/70), Ter119 (TER-119), CD4 (RM4-5),
CD3 (145-2C11), CD8 (53–6.7), B220 (RA3-6B2), IL7Ra (SB/
199), PE-Cy7-conjugated anti-c-Kit (2B8), APC-conjugated anti-
Sca-1 (E13-161.7) and FITC-conjugated CD34 (RAM34). Colony
forming unit-culture (CFU-C) assays, using fetal liver cells or bone
marrow cells, were performed as previously described [32]. Briefly,
fetal liver or bone marrow cells were cultured in 35-mm dishes in
triplicate in Methocult M3231 methylcellulose medium (StemCell
Tec., Vancouver, BC, Canada) supplemented with 20 ng/mL
recombinant mouse IL-3, 100 ng/mL mouse SCF, 200 ng/mL
mouse G-CSF and 10 ng/mL mouse EPO. Colonies were counted
on day 10.
Figure 3. Profound depletion of hematopoietic cells in adult mice carrying an Evi1 exon3 deletion. (A) Kaplan-Meyer survival curves
indicate significant lethality in Vav-iCre; Evi1fl3/fl3 mice, with a median survival of 7.7 weeks (Log rank test, Chi square p value ,0.0001). (B)
Hemograms for 6 to 9 week-old Vav-iCre; Evi1fl3/fl3 mice. These adult mice displayed leucopenia, severe anemia and thrombocytopenia. Mean 6 SEM
is indicated. *p,0.05, **p,0.01, ***p,0.001, unpaired t-test. (C) Flow cytometric profiles of bone marrow cells from Vav-iCre/+;Evi1fl3/fl3 and
littermate control mice (Evi1fl3/+ or Evi1fl3/fl3). HSC and progenitor cell subpopulations were detected by a combination of markers (KSL: c-Kit+, S: Sca-
1+, L: lineage2). We found a significant reduction of cells in Evi1-deleted samples, p = 0.00011 and p=0.0024, for KSL and KL, respectively (unpaired t-
test). (D) Colony forming counts for cells from bone marrow of Vav-iCre;Evi1fl3/fl3 and littermate control mice (Evi1fl3/+ or Evi1fl3/fl3). N = 3 for each
group, p = 0.0019 (unpaired t-test). No BFU-E and CFU-Mix colonies were identified.
doi:10.1371/journal.pone.0089397.g003
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Histology
Mice received a complete necropsy after which their tissues
were fixed in 10% neutral buffered formalin overnight and
embedded in paraffin. Embryos were fixed and embedded whole
before sectioning. Sections of 5 mm were stained with Hematox-
ylin and Eosin or Giemsa.
Magnetic Resonance Imaging and 3D reconstruction
Embryos were harvested at E15.5, euthanized and fixed in 4%
paraformaldehyde (PFA) with 2 mM Gd-DTPA (gadolinium-
diethylenetriaminepentacetate) as a contrast agent. Multi-embryo
imaging was conducted as previously described [33]. The raw MR
data were reconstructed as described previously [34]. The files
were analyzed using Amira 5.3.3 software.
In situ hybridization in embryos
Evi1 mRNA in situ hybridization was carried out using a full
length Evi1 cDNA probe [35] using standard protocols. Probes
were labeled using a DIG RNA Labeling Kit (Roche Applied
Science, Tokyo, Japan). Detection was via an anti-DIG antibody
coupled to alkaline phosphatase (Roche, Tokyo, Japan) followed
by staining with BCIP-NBT (Bromo-4-chloro-3-indolyl Phos-
phate/Nitro Blue Tetrazolium) (Nacalai, Tokyo, Japan) as
previously described [36].
Results
Deletion of Evi1 exon 3 results in postnatal lethality
Mice homozygous for an Evi1 exon 3 deletion (designed
Evi1dex3/dex3) have recently been generated and used to access the
function of Mecom in hematopoiesis ex vivo [18]. Deletion of
exon3 is predicted to prematurely abrogate the expression of
Mds1-Evi1 due to the presence of an out-of-frame stop codon in
exon 4 (Fig. 1A). Exon 3 also encodes the ATG translation start
site for Evi1 and Evi1d324 (Fig. 1A). Evi1dex3 is thus predicted to be
a Mecom null allele (Fig. S1A in File S1). We therefore expected
that similar to other Evi1 knockout mice [12,13,29], deletion of
Figure 4. Spontaneous lethal bone marrow depletion in mice harboring an Evi1 exon3 deletion in the hematopoietic system. (A)
Histology was performed on sick Vav-iCre; Evi1fl3/fl3 and littermate control mice. Bone marrow depletion was observed in the mutant mice. Adipose
tissue replaced the hematopoietic cells in the bone marrow. (B) Increased erythropoiesis in the spleen of Vav-iCre; Evi1fl3/fl3 mice. No visible border
was found between the red pulp and white pulp. Erythroid cells are shown by the arrows. Excess erythropoiesis in spleen likely happens to
compensate for bone marrow loss. (C) H&E stained sections of the brain of a dying Vav-iCre; Evi1fl3/fl3 mouse. Hemorrhages (red areas) were visible at
several locations (also see Fig. S3E in File S1). (D) Histological sections of tissues from dying Vav-iCre; Evi1fl3/fl3 animals showing bacteremia. Red
arrows indicate the presence of bacteria in alveolar capillaries. Giemsa stains reveal the presence of cocci or small rods within glomerular capillaries.
No sign of immune system defense (inflammatory cells) was observed despite the infection.
doi:10.1371/journal.pone.0089397.g004
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exon 3 would lead to embryonic lethality between E10.5 and E16
due to defects in HSC self-renewal and subsequent hematopoietic
failure. Surprisingly, this was not the case. Homozygous Evi1dex3/
dex3 knockout mice (Fig. S1B,C in File S1) were born with a
normal Mendelian ratio (Fig. 1B). They were indistinguishable
from their control littermates, there were no gross morphological
defects and they were normal in size (Fig. S1D in File S1). The
presence of grossly visible milk-filled stomachs a few hours after
birth also attested to their ability to feed, which was confirmed by
histology (Fig. S1E in File S1). However, several hours to a few
days after birth, Evi1dex3/dex3 mice became weak, lost weight and
eventually died, with no Evi1dex3/dex3 animals surviving longer
than three days (Fig. 1C,D). These results suggest that Evi1fl3
might encode a hypomorphic allele rather than a null allele.
Evi1fl3 encodes a hypomorphic allele
To determine whether Evi1fl3 encodes a hypomorphic allele we
used 59 RACE to confirm that exon3 was deleted from all Mecom
transcripts expressed in Evi1dex3/dex3 embryos. We also performed
RT-qPCR to quantify the level of the Mecom transcripts
expressed in Evi1dex3/dex3 embryos using primers located in exons
2 and 3, 3 and 4 or 13 and 14. No significant amplification was
detected in Evi1dex3/dex3 embryos using the two first sets of primers
(Fig. 1E), confirming that exon3 was deleted from all Mecom
transcripts in Evi1dex3/dex3 animals. Transcripts encoding Evi1
exons 13 and 14 were, however, produced at normal levels,
confirming that stable Evi1 transcripts are expressed in Evi1dex3/
dex3 embryos. Western blot analyses showed that proteins with a
similar size to Evi1, Evi1d105, and Evi1d324 were also expressed
in Evi1dex3/dex3 embryos (Fig. 1F). Evi1d105 is a splice variant
present in mouse but not in human tissues [37]. Deletion of exon3
thus did not appear to affect Evi1 protein translation as would
have been expected by removal of exon 3. We therefore decided to
look for alternative ATG translation start sites that might be
located downstream of exon 3. We found a potential ATG start
site in exon 4, which contains a Kozak sequence [38] and is in
frame with the rest of the protein. This start site is well conserved
in higher vertebrates and provides a better Kozak sequence than
the start site in exon 3 (Fig. 1G, S2). The use of this alternative
start site would remove 42 amino acids from the N-terminus of
Evi1 including the first zinc finger motif of the proximal Evi1 zinc
finger domain (Fig. S2 in File S1). Evi1d105, an isoform
specifically present in mice [37] and Evi1d324 would be similarly
affected since they share the same transcription start site as Evi1.
Figure 5. Cardiac malformations and failure in Evi1dex3/dex3 mice. (A) Transverse sections and (B) 3D reconstruction (left-ventral oblique view)
of hearts from Evi1dex3/dex3 or wild type littermate (+/+) E15.5 embryos analyzed by magnetic resonance imaging (MRI). The aorta (Ao), right ventricle
(RV), left ventricle (LV), ventricular septum (VS), trachea (Tr), aortic arch (AoA) and ductus arteriosus (DA) are indicated. Ventricular septal defect (VSD),
interrupted aortic arch (IAA) and common arterial trunk (CAT) were observed in Evi1dex3/dex3 hearts. (C) List of the congenital heart defects identified
in fifteen E15.5 embryos of various different genotypes by MRI and 3D reconstruction. (D) Hematoxylin and eosin staining of 5 mm sections of a sick
Evi1dex3/dex3 pup. Subcutaneous and other tissue edema (white spaces) was present, consistent with heart failure.
doi:10.1371/journal.pone.0089397.g005
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These results support the notion that Evi1fl3 encodes a hypomor-
phic allele that results from the expression of an N-terminally
truncated Evi1 protein initiated in exon 4.
Evi1dex3/dex3 newborn pups have a milder hematopoietic
phenotype than that observed in Evi1dex4/dex4 embryos
The embryonic lethality in Evi1 exon 4 knockout mice has been
ascribed to defective HSC self-renewal and subsequent hemato-
poietic failure. [12]. To determine whether Evi1dex3/dex3 embryos
have similar defects, we counted the number of two immunophe-
notypically defined HSC populations, c-Kit+, Sca-1+, lineage-
(KSL) and c-Kit+, lineage-, CD34+ (KL-CD34+) cells from E14.5
wild-type, Evi1dex3/+ and Evi1dex3/dex3 fetal livers (Fig. 2A). The
number of KSL HSCs and KL-CD34+ progenitor cells was
significantly reduced in Evi1dex3/dex3 fetal livers as compared to
wild type livers, while Evi1dex3/+ fetal livers presented an
intermediate phenotype (Fig. 2A). In addition, there was a slight
reduction in the number of B220+ B-lymphocytes (Fig. 2B) and
colony-forming cells (Fig. 2C) in E14.4 Evi1dex3/+ and Evi1dex3/
dex3 fetal livers. These results show that deletion of Evi1 exon 3
leads to a reduction in the number of HSC and progenitor cells,
but this deletion does not affect the differentiation of progenitors
once they are formed. This hematopoietic phenotype is milder
than that described for Evi1dex4/dex4 mice [12] as the HSC counts
were reduced by only 76% versus 93% for Evi1dex4/dex4 mice.
Blood counts from Evi1+/+, Evi1dex3/+ and Evi1dex3/dex3 newborn
animals (Fig. 2D) also showed that erythropoiesis was normal in
Evi1dex3/dex3 newborn animals. Mild leucopenia was however
detected, which equally affected all hematopoietic compartments.
Hypoproliferative thrombocytopenia was the most prominent
phenotype linked to the Evi1 exon 3 deletion. Histological analyses
showed that 31% of the Evi1dex3/dex3 pups had grossly visible focal
hemorrhages in various tissues at birth (4 out of 13 pups) (Fig. 2E),
while no control animals were seen with hemorrhagic lesions (0
out of 8 controls). These hemorrhages were unlikely to be the
cause of embryonic lethality, however, because other genetically
engineered mouse models with much lower platelet counts have
been shown to survive to adulthood [39].
Spontaneous lethal bone marrow failure in the
hematopoietic compartment of Evi1dex3/dex3 animals
To further characterize the hematopoietic phenotype linked to
the Evi1 exon3 deletion, we crossed Evi1fl3/fl3 animals with Vav-
iCre transgenic mice [40]. Vav-iCre is expressed in all hemato-
poietic, but few other cell types, and as expected Vav-iCre/+,
Evi1fl3/fl3 animals displayed a selective loss of Evi1 exon3 in the
hematopoietic compartment (Fig. S3A in File S1). These mice did
not die during prenatal development but instead died between 2.8
and 24.8 weeks of age (N= 37), with a median survival of 6.3
weeks (Fig. 3A). Heterozygous deletion of exon 3 did not affect the
mortality rate compared to control mice (Fig. 3A). Most mice
became weak and lost weight before dying (Fig. S3B in File S1).
Hemograms were subsequently performed on Vav-iCre/+,
Evi1fl3/fl3 weak animals and corresponding littermate controls +/
+, Evi1fl3/fl3. The hematopoietic phenotype was dramatic, with
severe thrombocytopenia, anemia and leucopenia in this condi-
Figure 6. Expression of Mecom mRNA in cardiac structures of wild type embryos. (A–D) Whole mount mRNA in situ hybridization to show
Mecom expression. A–C) Expression during subsequent stages of heart tube formation E8.5 (black brackets). D) At E9.5 Evi1 is expressed in the
endothelial cells and in the endocardium of the heart and in the mesenchyme of the aortic arches. Expression also includes a population of migrating
neural crest cells (white arrowhead). E–J) E10.5 Sagittal sections (from right to left) showing Evi1 in the aortic arches (a), mesenchyme of the
secondary heart field (black arrowheads), outflow and atrio-ventricular canal endocardium including the cushions.
doi:10.1371/journal.pone.0089397.g006
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Figure 7. Evi1 regulates the expression of other CHD genes during embryonic heart development. (A) The number of CHD genes
represented in Evi1 ChIP-Seq data (Evi1 bound genes) or in the list of genes regulated by Mecom. An enriched number of CHD genes were found
bound or regulated by Mecom (50 out of 143 genes), p = 0.0453 and p= 0.0276, respectively. These genes represent potential Mecom target genes in
heart development. (B) Mecom regulates the expression of 23 CHD genes, which contain Evi1-binding sites specifically in heart. Heart and head
(neural crest) tissues were harvested from WT and Evi1dex3/dex3 embryos of somite number 9 to 18. RT-qPCR assays were performed. Genes considered
to be mis-regulated in Evi1dex3/dex3 hearts were increased or decreased in expression by at least three fold in average for all samples of the same time-
point. These graphs are representative of two to five independent experiments.
doi:10.1371/journal.pone.0089397.g007
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tional exon 3 deletion (Fig. 3B). Moreover, the number of KSL
HSCs and KL progenitor cells in the bone marrow was close to
zero (Fig. 3C). In addition, no colonies could be formed from Vav-
iCre/+, Evi1fl3/fl3 bone marrow cells ex vivo (Fig. 3D). These
results demonstrated a profound depletion of HSC and progenitor
cells as well as downstream hematopoietic cells. Histological
analysis of the bones of sick animals confirmed the spontaneous
bone marrow hypoplasia (Fig. 4A), as hematopoietic cells were few
or undetectable in the bone marrow cavity. This phenotype was
accompanied by compensatory erythropoiesis in the spleen
(Fig. 4B). Erythrophagocytosis with rosettes (Fig. S3C in File S1)
was also identified in two animals, demonstrating immune
perturbations. Bone marrow depletion can lead to hemorrhages
due to lack of megakaryocytes and platelets. Indeed, bleeding in
vital organs like the brain was observed in Vav-iCre/+, Evi1fl3/fl3
mice and was likely to be one major cause of lethality in these
animals (Fig. 4C, S3D in File S1). Another major etiology was
severe bacterial infections due to loss of immune defense. Gram-
positive bacteria were found in the blood of the lungs, kidneys, and
hearts of Vav-iCre/+, Evi1fl3/fl3 mice, indicating bacteremia
(Fig. 4D). Collectively, these results describe a spontaneous lethal
bone marrow failure upon deletion of Evi1 exon3 in the
hematopoietic system. This hypomorphic phenotype is consistent
with the profound HSC depletion seen in Evi1 exon 4 conditional
knockout at E10.5–16.5 [12], but it occurs at a much later stage, in
Evi1 exon 3 deleted adult mice.
Congenital heart defects in Evi1dex3/dex3 newborn mice
Since it was unlikely that the perinatal lethality observed in
Evi1dex3/dex3 mice was caused by the hematopoietic defects we
looked for other possible causes. We used magnetic resonance
imaging (MRI) to visualize organ formation in six Evi1dex3/dex3,
three Evi1dex3/+ and six E15.5 control littermates, as previously
described [41]. Structural abnormalities were observed in the
hearts of all six Evi1dex3/dex3 embryos (Fig. 5A,B), while small
benign bilateral cysts were observed in the jugular lymphatic sacks
of two Evi1dex3/dex3 embryos (Fig. S4 in File S1). No defects were
observed in wild type or heterozygous mutant animals. Evi1dex3/
dex3 embryos displayed several congenital heart defects (Fig. 5C).
All six Evi1dex3/dex3 embryos had ventricular septal defects
(VSD) - failure to form the septum between the ventricles of the
heart (Fig. 5B,C).
Common arterial trunk (CAT), where two great arteries fail to
separate and leave the heart as one common vessel, was also
observed in 3 out of 6 Evi1dex3/dex3 embryos. Double outlet right
ventricle (DORV), where both the aorta and pulmonary trunk
leave one ventricle, was also observed in half of the Evi1dex3/dex3
embryos (Fig. 5B,C). In addition, overriding aorta (aorta
originating just above the VSD) was seen in one Evi1dex3/dex3
embryo. Finally, aortic arch formation impairments were found in
4 out of 6 Evi1dex3/dex3 embryos (Fig. 5B,C). These impairments
were manifested as an interrupted aortic arch (IAA), with a
complete discontinuation between the ascending and descending
parts of the aorta. These type of congenital heart defects are
known to be viable in utero but lethal during the neonatal phase of
life for other mouse knockouts [42], and thus likely represent the
major cause of the perinatal lethality seen in Evi1dex3/dex3 pups.
Consistent with this, heart failure was sometimes accompanied by
oedema and congested lungs in Evi1dex3/dex3 pups (Fig. 5D).
Mecom expression in the developing heart
We next examined Mecom expression by mRNA in situ
hybridization. At E8.5 Mecom was expressed in the forming heart
tube (Fig 6A-C). By E9.5-E10.5 Mecom expression could clearly be
localized to the endothelial cells and in the endocardium (Fig. 6D–
J), and its expression was strong in the cushions of the atrio-
ventricular canal (AVC). In the outflow tract, Mecom was not
clearly expressed in the myocardium outer layer, but rather in the
mesenchyme cells that are composed of cardiac neural crest.
There was also clear expression in the neural crest cells which
generates the majority of mesenchyme of aortic arches 1 and 2
(Fig 6E). We also saw Mecom in the stream of neural crest cells
situated behind the heart (Fig 6D, arrowhead). Finally, there was
additional Mecom signal in the mesenchyme cells of the secondary
heart field (Fig 6E,F).Overall, we found that Mecom expression
overlaps with the key cell populations in which defects could lead
to the heart malformations we have described, especially the
endocardium, the endocardial cushions, and the neural crest cells
[42,43]
Evi1 controls the expression of genes that regulate heart
development
How might Evi1 act to control heart development? Because
Evi1 is a transcription factor that can both activate or repress its
target genes [16] we hypothesized that it might be part of the
transcriptional program that controls heart development. To
Table 2. Overview of Major Reported Expression Domains.
Gene Reported Expression Domains References
Mecom AA, CC/HT, End+Csn, NC, SHF
Adam9 End+Csn, Myo [56,57]
Bmp4 AA, Myo, NC, OFT, SHF [58,59,60]
Bmpr2 AA, End, Myo, NC [58,59,60]
Cav1 End [61]
Chd7 AA [62]
Cited2 AA, CC/HT, End+Csn, Myo, OFT [63,64]
Crkl AA, NC [65]
Cxcr4 AA, Myo [66]
Flna AA, End+Csn, NC, OFT [67]
Foxp1 End+Csn, Myo, OFT [68]
Gata6 End+Csn, Myo, OFT, NC [69,70]
Hey1 AA, End, OFT [71,72,73]
Jag1 AA, End, OFT [71,74]
Jun AA, End+Csn, OFT, SHF [75]
Nf1 AA, End+Csn, Myo, NC [76]
Nrp2 NC [77,78]
Psen1 AA, End+Csn, Myo, NC, OFT [79,80]
Rarg AA [81]
Rxra AA, End+Csn, Myo, NC, OFT [82]
Sox4 End+Csn, Myo [68,83]
Tgfbr2 AA, CC/HT, End+Csn, Myo, NC [84,85,86]
Thbs1 End, Myo [87]
Key
AA – Aortic Arch and Aortic Arch Arteries.
CC/HT - Cardiac Crescent/Heart Tube.
End – Endocardium (+Csn – including Cushions).
Myo – Myocardium.
NC –Neural Crest (Cardiac).
OFT – Outflow Tract.
SHF – Secondary Heart Field.
doi:10.1371/journal.pone.0089397.t002
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determine this, we searched the Mouse Genome Informatics
(MGI) database [44] and found 143 Congenital Heart Defect
(CHD) genes whose mutant heart phenotypes were similar to those
observed in Evi1dex3/dex3 mice (Table S1). These genes were linked
to the MGI Mammalian Phenotype identifications MP:0010402
(VSD), MP:0002633 (persistent truncus arteriosis, another name
for CAT), MP:0000284 (DORV), MP:0004157 (IAA), and
MP:0000273 (overriding aorta) [45]. We cross-compared these
143 genes with available EVI1 ChIP-Seq and differential
microarray data [16]. Forty-two of these 143 genes contain
known EVI1-binding sites, which constituted a significant
enrichment (p = 0.0453, Chi-square with Yates correction),
suggesting them as possible Evi1-target genes in heart (Fig. 7A).
Similarly, the expression of 26 genes is known to be affected by
Evi1 siRNA knock-down in SKOV3 cells (significant enrichment,
p = 0.0276, Chi-square with Yates correction) [16], while 18 genes
contain known Evi1-binding sites and are also effected by Evi1
siRNA knockdown (Fig. 7A, Table 1). This represents a very
significant enrichment of CHD genes in Evi1 direct target genes
(p,0.0001, Chi-square with Yates correction), strongly suggesting
a functional involvement of these EVI1 target genes in heart
development.
These computational comparative analyses have provided a list
of 50 genes that are likely to be enriched for genes that are
regulated by Evi1 during heart development (Table S1, Figure 7A).
To provide additional evidence for this, we dissected hearts, and
heads as a control, from a range of Evi1dex3/dex3 embryos between
E8 and E10, in order to determine if these candidates are
deregulated due to the disruption of Mecom activity.
We extracted mRNA from mutant and wild-type embryonic
hearts and heads, and performed reverse transcription (RT) and
qPCR to quantitate the level of expression of 31 of the Evi1
candidate target genes (Fig. 7B, S5). Due to limited amount of
RNA from embryonic heart, we chose to assess the 18 CHD genes
previously found occupied and regulated by Evi1, plus 14 CHD
genes bound by Evi1. We then used the 22A¨A¨Ct method [30] to
calculate the fold change in expression between wild type and
mutant embryos. We found that the Evi1 exon3 deletion had no
effect on the expression of eight genes (Fig. S5 in File S1), while
three were downregulated and 20 were upregulated in expression
in Mecom mutant hearts (Table1, Fig. 7B). This was consistent with
MECOM being a known dynamic modulator of transcription that
can either activate or repress genes, depending on the recruitment
of coactivators or corepressors [46].Of the 13 genes regulated by
Evi1 both in cardiac development and in SKOV3 ovarian
carcinoma cells, 9 genes showed Evi1-mediated changes in
expression level in a similar manner (Jun, Thbs1, Adam9, Hey1,
Jag1, Nrp2, Rarg, Sox4, and Tgfbr2). Some of these regulatory
relationships were also consistent with previous reports. For
instance, in cell line models, Jun expression was found up-
regulated by Evi1 through its direct binding to Jun promoter
[16,47–50]. The Sox4 transcription factor and Evi1 cooperate to
induce myeloid leukemia [51]; and Evi1 was shown to bind to
Sox4 promoter and regulate its gene expression [16], providing
evidence of transactivation of Sox4 by Evi1. Collectively, these
results demonstrate that Evi1 modulates, in embryonic heart, the
expression of genes that are important for controlling heart
development.
We also performed a literature search to compare the gene
expression patterns of these Mecom-deregulated factors to the
Mecom embryonic heart expression pattern we describe (Fig.6).
This analysis (Table 2) confirmed common expression in the
endocardium and endocardial cushions, as well as in the aortic
arches and outflow tract - especially in the neural crest cells.
Discussion
Our results demonstrate that deletion of Evi1 exon 3 produces a
hypomorphic allele compared to previous studies involving Evi1
exons 4 and 7, where their removal produced complete null alleles
[12,29]. Deletion of exon 3 indeed does not affect Evi1, Evi1d105
[37] and Evi1d324 protein production but does block the
generation of Mds1-Evi1 protein production. All Evi1 isoform
proteins expressed in these mice are expected to carry a 42 amino
acid truncation at the N-terminus that constitutes nearly 4% of the
protein. Such truncated proteins would be predicted to lack one
zinc finger motif out of the seven present in the proximal DNA-
binding site. It is not completely clear if and how this truncation
affects Evi1 transcriptional activity or function. Several findings
suggest that translation from Evi1 exon4 ATG start site produces a
functional protein. First, the exon4 contains the best Kozak
sequence with highest cross-species conservation. Thus, it is
possible that the exon4 translation start site may be naturally
produced in vivo. Secondly, a previous study has suggested that
Evi1 protein initiated from exon 4 is oncogenic and able to give
rise to leukemic clones in mice [52]. Retroviral insertional
mutagenesis screens in mice have identified Evi1 isoform as a
targeted mutant gene in myeloid leukemia [53,54]. Sequencing of
the retroviral insertion sites from these tumors has shown that the
majority of insertions are located upstream of Evi1 coding
sequence, where they serve to upregulate the expression of
oncogenic Evi1 but block the expression of Mds1-Evi1. The
genomic region located between exons 3 and 4 is only 4 kb
compared to the rest of the Evi1 upstream region which is 90 kb in
size, thus providing 23 times less chance to contain a retrovirus
insertion by random chance. However, retroviral insertions
located between exon 3 and 4 have been described in tumors,
which would serve to activate Evi1 translation from the alternative
translation start site located in exon 4 [52].
The profound embryonic lethal disruption of HSC renewal seen
in other studies [12,13] was not present in our Evi1dex3/dex3
mutant embryos and newborn pups. However, we did identify a
dramatic perturbation of hematopoietic repopulation activity in
Vav-iCre/+, Evi1fl3/fl3 young adult mice. To our knowledge, there
is no current genetically-modified mouse model that mimics
spontaneous bone marrow failure as seen in the Vav-iCre/+,
Evi1fl3/fl3 mice. They therefore constitute the first model of
spontaneous lethal bone marrow failure in the adult. Surprisingly,
the hypomorphic deletion of Evi1 could delay the phenotype of
hematopoietic failure and the appearance of bone marrow
depletion. This in is line with a previous study [21] that specifically
implicated Mds1-Evi1 in the regulation of long term HSC
repopulating activity [55] and Evi1 in short term HSC renewal
activity [12,29].
The delay in acquisition of the hematological phenotype in
Evi1dex3/dex3 knockout mice allowed the embryos to survive to the
perinatal period and the congenital heart defects found in these
mice to be observed. Our results are also consistent with those
reported for Evi1 exon 7 knockout mice published in 1997, which
reported that E10.5 Evi1-/- mutant embryos displayed heart
failure. Although their data based on only one histology section are
not clear, Evi1dex7/dex7 knockout embryos were reported to display
arrested heart development with a looping defect of the posterior
part of the heart and a poorly developed constriction between atria
and ventricle [29], which is different from our findings. At the time
of this previous study, the technologies to study embryonic cardiac
development were based only on histological methods, which
could not allow precise interpretations of the pathology. In our
studies we used MRI and 3D modeling to clearly define the
Evi1 Is Critical for Heart and Blood Development
PLOS ONE | www.plosone.org 11 February 2014 | Volume 9 | Issue 2 | e89397
pathology and heart developmental defects in Evi1 exon 3
knockout embryos.
We provide evidence that Mecom belongs to a transcriptional
regulatory network that controls heart development. Mecom
expression overlaps with the expression of multiple other factors
required to form the heart (Table 2). These factors can be Mecom
targets, and their expression is deregulated expression in the
Evi1dex3/dex3 mutant heart. Of particular interest may be factors in
the Notch and TGFb pathways as that Mecom or its homologues
interact with these pathways [22]. In the endocardium for
example, there is clear overlap of Mecom with the Notch ligand
Jag1 and the TGFb receptor Tgfbr2.
The endocardium is major site of Mecom expression in the
heart, and it is possible that Mecom regulates gene expression
directly in this tissue. The cushions cells of the AVC originate from
endocardium via an epithelial–mesenchymal transition, and they
form the partition between the ventricles and the atria (atrio-
ventricular canal and later valves). This partition provides the
matrix for the growing ventricular and atrial septa [42,43].
Another possible site of Mecom action is in the neural crest cells.
The spectrum of phenotypes seen in the Evi1dex3/dex3 knockout
heart could also be attributed to defects in these cells causing
disrupted remodelling of the aortic arches, and to a failure to
septate the outflow tract [43]. Further studies (perhaps using a
floxed-Evi1 null allele [12] and specific Cre lines) can be used
address if Mecom is required in a particular heart cell population,
or in multiple populations to drive heart development.
Supporting Information
File S1 Figure S1, Targeting and knockout of Evi1
exon3. Figure S2, An alternative protein translation site
located in Evi1 exon 4 and structure of the translated
protein. Figure S3, Deletion of Evi1 exon 3 in the
hematopoietic compartment. Figure S4, Small bilateral
cysts in jugular lymphatic sacks of Evi1dex3/dex3 embry-
os. Figure S5, CHD gene expression in Evi1dex3/dex3
embryos.
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Table S1 List of 143 congenital heart defect genes with
similar heart phenotypes as thosed observed in Evi1dex3/
dex3 mice. All 143 genes linked to the Mammalian Phenotype
identifications MP:0010402 (VSD), MP:0002633 (persistent trun-
cus arteriosis, other name for CAT), MP:0000284 (DORV),
MP:0004157 (IAA), MP:0000273 (overriding aorta) in the MGI
database [88]. The genes found in previous Evi1 ChIP-Seq and
microarray experiments [89] provide potential Mecom target
genes in heart development.
(XLSX)
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